Abeona Therapeutics ABEO Q3 2026: ZEVASKYN Ramp Hits 15 Treatments
As seen on the 24/7 Wall St. homepage on November 9, 2026.
The narrower loss leans on a $6.5 million non-cash warrant gain, while revenue came in missing expectations after one treatment batch failed an identity assay and could not be booked. The ZEVASKYN ramp is the line to track: six treatments completed in the quarter, 15 since launch, with Medicare NTAP reimbursement live as of October 1.
Continue ReadingShow less
Abeona Therapeutics reported a loss of $0.08 per share for the third quarter of 2026, beating the consensus estimate of a $0.17 loss. A $6.5 million non-cash gain from the change in fair value of warrant liabilities shaped much of that result, so operating performance alone did not drive it.
Revenue of $13.49 million came in missing expectations against the $14.82 million estimate, and the shortfall has a specific explanation: one ZEVASKYN treatment batch failed an identity assay release criterion and could not be recognized as revenue. Abeona had flagged that possibility as early as August, so the miss was not a complete surprise to investors following the company closely.
ZEVASKYN commercial adoption continued to build through the quarter. Six treatments were completed, bringing the cumulative total to 15 since launch, and sequential revenue climbed from $11.38 million in Q2 2026. The qualified treatment center network expanded to eight sites, with four now holding firsthand treatment experience.
Sponsored
Starting October 1, Medicare patients became eligible for NTAP supplemental reimbursement under the FY2027 IPPS Final Rule, a development management views as a meaningful catalyst for hospital adoption. That reimbursement mechanism had not yet been in place during the quarter being reported, so its impact will first show up in Q4 numbers.
Abeona also announced the acquisition of ABO-801, a Phase 3-ready oral tablet of fluticasone propionate targeting eosinophilic esophagitis, which it acquired from Ellodi Pharmaceuticals for $20 million in stock plus up to $30 million on FDA approval and additional sales milestones. A $30 million private placement is being used to fund pipeline development and continued ZEVASKYN commercialization, alongside a cash balance of $134.9 million as of September 30, 2026, which excludes the PIPE proceeds. The batch-failure risk remains a live concern: release specifications are based on a limited clinical dataset, and uncertainty persists over whether the FDA will revise them.
Mentioned: ABEO